Phase 4 Completed N=376 Treatment

A Study of 0.15% Brimonidine Tartrate in Patients With Primary Open Angle Glaucoma and Ocular Hypertension

Glaucoma, Open-Angle · Hypertension

Source: ClinicalTrials.gov NCT02003534 ↗

Enrolled (actual)

376

Serious AEs

0.0%

Results posted

Jul 2014

Primary outcomePrimary: Change From Baseline in Intraocular Pressure (IOP) in the Study Eye — 25.4; -6.3 Millimeters of Mercury (mmHg)

Summary

This study will evaluate 0.15% brimonidine tartrate in patients with primary open angle glaucoma and ocular hypertension.

Outcome Measures

Outcome	Result	p-value
PRIMARY Change From Baseline in Intraocular Pressure (IOP) in the Study Eye	25.4; -6.3	—

Eligibility Criteria

Inclusion Criteria

Diagnosis of open-angle glaucoma or ocular hypertension

Exclusion Criteria

Used Alphagan® in previous 3 months

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02003534). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.